Aktis Oncology, Inc. (AKTS)
| Market Cap | 1.08B |
| Revenue (ttm) | 8.28M +1,394.0% |
| Net Income | -67.07M |
| EPS | -5.25 |
| Shares Out | 55.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,825 |
| Open | 19.09 |
| Previous Close | 19.50 |
| Day's Range | 18.81 - 19.71 |
| 52-Week Range | 14.72 - 29.16 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.50 (+61.13%) |
| Earnings Date | May 11, 2026 |
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A... [Read more]
Financial Performance
In 2025, Aktis Oncology's revenue was $6.50 million, an increase of 336.92% compared to the previous year's $1.49 million. Losses were -$63.73 million, 44.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AKTS stock is "Strong Buy." The 12-month stock price target is $31.5, which is an increase of 61.13% from the latest price.
News
Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. “We continue to build momentum toward delivering a new class…
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology to Present at the BofA Securities Health Care Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Study update
AKY-2519, a B7-H3-targeted radioconjugate, has entered phase I-B trials for mCRPC, with a parallel basket trial in other solid tumors planned for late 2026. Imaging and dosimetry data will be presented at ASCO, and preliminary clinical data are expected in 2027.
Aktis Oncology initiates clinical trial of AKY-25191
Aktis Oncology (AKTS) announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate cancer. The mCRPC-dedicated Phase 1b trial is part of...
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology initiated with an Outperform at William Blair
William Blair initiated coverage of Aktis Oncology (AKTS) with an Outperform rating. The company is positioned to become a radiopharmaceuticals leader by using miniproteins to address novel targets wi...
Aktis Oncology appoints Gormley as independent director of Board of Directors
Aktis Oncology (AKTS) announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company’s newly established Science and Technology…
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharma...
Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps a Buy rating on the shares following the Q4 report.
Aktis Oncology announces FDA clearance of AKY-25191 trial
Aktis Oncology (AKTS) announced the FDA cleared the investigational new drug applications for the company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjuga...
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharma...
Aktis Oncology Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a novel radiopharmaceutical platform with lead programs targeting Nectin-4 and B7-H3, both showing promising early clinical and imaging data. Robust supply chain, strong financials, and strategic partnerships position it for broad impact and sustained growth.
Aktis Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Aktis Oncology (AKTS) with a Buy rating and $30 price target The company is expanding the potential of targeted radiotherapy with its miniprotein platform, the…
Aktis Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Radiopharmaceuticals are poised for major growth, with new miniprotein binder technology enabling first-in-class therapies targeting Nectin-4 and B7-H3. Robust supply chain, strategic partnerships, and a strong team support rapid clinical advancement and broad market potential.
Aktis Oncology to Present at Upcoming March Investor Conferences
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to larg...
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
Aktis Oncology (AKTS) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic…
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to larg...
Aktis Oncology initiated with an Outperform at Leerink
Leerink initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $31 price target The firm is positive on the Aktis story as the company aims to expand the…
Aktis Oncology initiated with a Buy at BofA
BofA initiated coverage of Aktis Oncology (AKTS) with a Buy rating and $34 price target Following a strong public debut, the firm sees further potential upside for shares driven by…
Aktis Oncology initiated with a Buy at TD Cowen
TD Cowen analyst Tyler Van Buren initiated coverage of Aktis Oncology (AKTS) with a Buy rating and no price target The firm says the company’s miniprotein technology has the opportunity…
Aktis Oncology initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Aktis Oncology (AKTS) with an Overweight rating and $30 price target The company has an “attractive” platform for developing radiopharmaceutical therapies, a novel means...
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large pa...
Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO
With the first biotech IPO of the year, Aktis Oncology blew past expectations, with shares jumping on the first day of trading. LATEST IPOS AND DIRECT LISTINGS: Aktis Oncology (AKTS)…